Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Is China A Black Swan For Big Pharma? (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Spend a week in Shanghai these days and you hear a lot about how the Big Pharma model is broken. China's life sciences leaders - many of whom are returnees from the U.S. - are talking about this openly, much like industry leaders now do in the U.S. The difference is that many executives on the ground here believe that China is evolving into a laboratory for doing things differently, a catalyst for disruptive innovation that may propel the pharma industry into changing how it develops and delivers drugs

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts